Tag : ALK-POSITIVE NON-SMALL CELL LUNG CANCER
The 7-year CROWN update showed lorlatinib providing durable PFS and sustained intracranial disease control vs. crizotinib in advanced ALK+ NSCLC. A consistent long-term safety profile and sustained benefit across patient subgroups further support lorlatinib as the preferred first-line standard of care.
